156 related articles for article (PubMed ID: 23009178)
21. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
22. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
23. [Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis].
Cao F; Zhang L; Wang S; Zhong D; Wang Y
Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):146-54. PubMed ID: 25800570
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cui S; Ni Y; Zhao Y; Li Z; Xiong L; Liu J; Liang X; Jiang L
Lung Cancer; 2019 Jun; 132():45-53. PubMed ID: 31097093
[TBL] [Abstract][Full Text] [Related]
25. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.
Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897
[TBL] [Abstract][Full Text] [Related]
26. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
27. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
28. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
29. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
[TBL] [Abstract][Full Text] [Related]
30. Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.
Dong ZY; Zhai HR; Hou QY; Su J; Liu SY; Yan HH; Li YS; Chen ZY; Zhong WZ; Wu YL
Oncologist; 2017 Jan; 22(1):61-69. PubMed ID: 28126915
[TBL] [Abstract][Full Text] [Related]
31. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
[TBL] [Abstract][Full Text] [Related]
32. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
33. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
34. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer.
Suzuki H; Toyota M; Carraway H; Gabrielson E; Ohmura T; Fujikane T; Nishikawa N; Sogabe Y; Nojima M; Sonoda T; Mori M; Hirata K; Imai K; Shinomura Y; Baylin SB; Tokino T
Br J Cancer; 2008 Mar; 98(6):1147-56. PubMed ID: 18283316
[TBL] [Abstract][Full Text] [Related]
35. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
[TBL] [Abstract][Full Text] [Related]
37. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
38. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
39. Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
Deng LL; Gao G; Deng HB; Wang F; Wang ZH; Yang Y
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2613-2624. PubMed ID: 31463717
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
Wang Q; Gao W; Gao F; Jin S; Qu T; Lin F; Zhang C; Zhang J; Zhang Z; Chen L; Guo R
BMC Cancer; 2021 May; 21(1):602. PubMed ID: 34034713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]